Department of Medicine and Liver Center, Yale University School of Medicine, New Haven, CT 06520-8019, USA.
Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G126-35. doi: 10.1152/ajpgi.00522.2010. Epub 2010 Apr 15.
Multidrug resistance protein 4 (MRP4; ABCC4) is an ATP binding cassette transporter that facilitates the excretion of bile salt conjugates and other conjugated steroids in hepatocytes and renal proximal tubule epithelium. MRP4/Mrp4 undergoes adaptive upregulation in response to oxidative and cholestatic liver injury in human and animal models of cholestasis. However, the molecular mechanism of this regulation remains to be determined. The aryl hydrocarbon receptor (AhR) and NF-E2-related factor 2 (Nrf2) play important roles in protecting cells from oxidative stress. Here we examine the role of these two nuclear factors in the regulation of the expression of human MRP4. HepG2 cells and human hepatocytes were treated with the AhR and Nrf2 activators, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3-methylcholanthrene (3-MC), or oltipraz and other nuclear receptor agonists. TCDD, 3-MC, and oltipraz significantly increased MRP4 expression at mRNA and protein levels. Computer program analysis revealed three Xenobiotic response element (XRE) and one Maf response element sites within the first 500 bp of the MRP4 proximal promoter. Luciferase reporter assay detected strong promoter activity (53-fold higher than vector control) in this region. TCDD and 3-MC also induced promoter activity in the reporter assays. Mutation of any of these XRE sites significantly decreased MRP4 promoter activity in reporter assays, although XRE2 demonstrated the strongest effects on both basal and TCDD-inducible activity. EMSA and chromatin immunoprecipitation assays further confirmed that both AhR and Nrf2 bind to the proximal promoter of MRP4. Our findings indicate that AhR and Nrf2 play important roles in regulating MRP4 expression and suggest that agents that activate their activity may be of therapeutic benefit for cholestasis.
多药耐药蛋白 4(MRP4;ABCC4)是一种 ATP 结合盒转运蛋白,可促进肝细胞和肾近端小管上皮中胆汁盐缀合物和其他缀合甾体的排泄。MRP4/Mrp4 在人类和动物胆汁淤积模型的氧化和胆汁淤积性肝损伤中发生适应性上调。然而,这种调节的分子机制仍有待确定。芳香烃受体(AhR)和核因子-2 相关因子 2(Nrf2)在保护细胞免受氧化应激方面发挥重要作用。在这里,我们研究了这两个核因子在调节人 MRP4 表达中的作用。用 AhR 和 Nrf2 激活剂 2,3,7,8-四氯二苯并-p-二恶英(TCDD)、3-甲基胆蒽(3-MC)或奥替普拉和其他核受体激动剂处理 HepG2 细胞和人肝细胞。TCDD、3-MC 和奥替普拉显着增加了 MRP4 在 mRNA 和蛋白质水平上的表达。计算机程序分析显示,MRP4 近端启动子的前 500bp 内有三个外源性反应元件(XRE)和一个 maf 反应元件位点。荧光素酶报告基因检测显示该区域具有很强的启动子活性(比载体对照高 53 倍)。TCDD 和 3-MC 也在报告基因检测中诱导启动子活性。在报告基因检测中,任何 XRE 位点的突变均显着降低了 MRP4 启动子活性,尽管 XRE2 对基础和 TCDD 诱导的活性均具有最强的影响。EMSA 和染色质免疫沉淀测定进一步证实 AhR 和 Nrf2 均与 MRP4 的近端启动子结合。我们的研究结果表明,AhR 和 Nrf2 在调节 MRP4 表达中起重要作用,并表明激活其活性的药物可能对胆汁淤积症具有治疗益处。